logo
Acura Kills The TLX After Only Selling 7,478 Of Them In 2024

Acura Kills The TLX After Only Selling 7,478 Of Them In 2024

Yahoo15 hours ago
While the Acura Integra just got a mid-cycle refresh, the larger TLX will soon get the axe. Automotive News reports the midsize sedan will end production by the end of the month, and since it's already July 23, that means the TLX only has days to live, not weeks. RIP in peace, Acura TLX.
Granted, it isn't like the TLX was a huge seller. Last year, Acura only sold 7,478 examples in the U.S., down from 16,731 sales in 2023. Meanwhile, 2023 was a much better year for the TLX than 2022 was, when it still only found 11,508 buyers. For comparison, BMW sold 25,315 examples of the 5 Series here in 2024 and moved 22,401 units in 2023. Considering how poorly it's been selling, it isn't terribly surprising that Acura would decide to pull the plug.
That said, it doesn't sound like it's entirely the TLX's fault. In order to prep its Marysville Auto Plant to build electric vehicles, Acura moved Accord, Integra and TLX production to the same line, which likely limited how many TLXs it could build. "Those production changes are crimping their sales because they can't build, and with an Accord facelift on the horizon, they have to decide whether to invest in both vehicles or just let the TLX go," Stephanie Brinley, associate director of S&P Global Mobility, told AutoNews.
Read more: These Are The Worst Transmission Recalls Of The Last 5 Years
Only A Matter Of Time
Then again, the deck was also stacked against the TLX's success, even before the first example rolled off the assembly line. It was, after all, a new sedan in a world that no longer likes sedans. Instead, most buyers want a crossover of some sort. Even if you're just looking at luxury vehicles, sedans reportedly dropped from 22% of the market in 2022 to 18% in 2024.
"The migration to utility vehicles has just not stopped, even in the luxury segment," Brinley told AutoNews. "Luxury sedans are still more popular in the luxury segment relatively than they are in the mainstream segment, but even so, the share keeps dropping."
The other issue, of course, was that even though the TLX and Acura's performance version, the TLX Type S, were pretty darn good cars, they both competed in seriously crowded segments with long-established players, as well as newcomers such as the Cadillac CT5 and Genesis G80. And while you could expect the TLX to cost less to maintain and repair in the long run, it struggled to stand out. Sure, it came with a fancy all-wheel drive system and didn't cost quite as much as some other cars in the segment, but clearly, that wasn't enough to bring in a steady stream of paying customers.
Then again, prices on used TLX Type Ss are already getting down into the low $30,000 range, so maybe the upside here is that you'll soon be able to pick up a pre-owned, all-wheel-drive TLX with 355 horsepower in the mid-to-high twenties. So at least there's that. It's just too bad Acura didn't offer it with a manual transmission.
Want more like this? Join the Jalopnik newsletter to get the latest auto news sent straight to your inbox...
Read the original article on Jalopnik.
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Cardinal Health expands urology focus with $1.9bn Solaris Health deal
Cardinal Health expands urology focus with $1.9bn Solaris Health deal

Yahoo

time19 minutes ago

  • Yahoo

Cardinal Health expands urology focus with $1.9bn Solaris Health deal

US drug distributor Cardinal Health has signed a $1.9bn agreement to acquire a majority stake in Solaris Health from Lee Equity Partners. The deal aims to expand the Specialty Alliance, the distributor's multi-speciality management services organisation (MSO) platform, in which Cardinal will gain a stake of around 75%. The acquisition will also create the Urology Alliance, comprising a collaborative network of urology providers within Cardinal's Specialty Alliance MSO, as well as resonate with plans to expand the delivery of urological patient care. Cardinal's Solaris buyout complements its recent acquisitions of Urology America, Potomac Urology, and Academic Urology & Urogynaecology, signalling its urologic strategy. The transaction is expected to be completed by the end of this year, pending customary closing conditions. Cardinal Health CEO Jason Hollar stated that growing the Speciality Alliance is a 'top priority' for the company, with the latest urology purchase leaving it 'well-positioned to meet the comprehensive needs of community urologists through the robust combined capabilities of the Specialty Alliance, Specialty Networks and Cardinal Health'. Research indicates there is a shortage of urologists in the US, with 62% of US counties lacking a practising urologist and just one new urologist entering the field for every ten retiring. The figures lead to challenges in the broader field, including delayed diagnoses, increased rates of advanced-stage conditions, and significant health disparities, with these particularly pronounced in rural communities. GlobalData's senior medical analyst Selena Yu foresees Cardinal's acquisition as reflecting a shift from drug distribution with a 'lower profit margin, towards higher margin speciality care in urology'. Yu said: 'MSOs help streamline backend work like billing and staffing to allow for physicians to focus on care. 'Additionally, with a large network of specialists, patients can receive care in the same region by different care specialists, which will reduce wait times and improve care continuity. Additionally, the Cardinal Health Alliance has other specialities like oncology specialists, which makes referrals more streamlined.' Cardinal's acquisition coincided with the release of its Q4 2025 financials. The company's profits per share came in at $2.08, beating the forecasted $2.03, yet profits for the quarter came in at $60.2bn, below the $60.92bn forecast, prompting a pre-market stock drop of more than 11% on 12 August. Cardinal's share price has since recovered to a drop of around 6% to $147.05 per share, down from $157.66 per share at market close on 11 August. "Cardinal Health expands urology focus with $1.9bn Solaris Health deal" was originally created and published by Medical Device Network, a GlobalData owned brand. The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site. Effettua l'accesso per consultare il tuo portafoglio

Texas sues Eli Lilly for allegedly bribing providers to prescribe its medications
Texas sues Eli Lilly for allegedly bribing providers to prescribe its medications

Yahoo

time19 minutes ago

  • Yahoo

Texas sues Eli Lilly for allegedly bribing providers to prescribe its medications

WASHINGTON (Reuters) -Texas Attorney General Ken Paxton on Tuesday sued U.S. drugmaker Eli Lilly for allegedly "bribing" providers to prescribe its medications. The attorney general's office said in a statement that the company bribed and illegally induced medical providers to prescribe its most profitable drugs, including the GLP-1 medications Mounjaro and Zepbound, used for weight loss and diabetes treatment. "Big Pharma compromised medical decision-making by engaging in an illegal kickback scheme," Attorney General Paxton said. The lawsuit builds upon Attorney General's previous legal action to hold drug manufacturers accountable for fraud and abuse, the statement added. Last year, Paxton had sued insulin manufacturers, including Lilly and pharmacy benefit managers (PBMs), alleging that manufacturers artificially raised the prices of insulin and then paid a significant, undisclosed portion back to the PBMs for preferential treatment in return. Eli Lilly did not immediately respond to a Reuters request for comment. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store